Selvita

What Selvita does

Selvita S.A. is a Poland-headquartered, publicly listed contract research organization (CRO) founded in 2007 and traded on the Warsaw Stock Exchange (WSE:SLV). Following a 2019 corporate split that separated proprietary oncology drug discovery into Ryvu Therapeutics, Selvita has operated as a pure-play CRO delivering integrated drug discovery and drug development services to pharmaceutical and biotechnology companies across Europe, North America, and Asia. The company employs more than 950 scientists across research facilities in Kraków, Poznań, and Wrocław (Poland) and Zagreb (Croatia), with commercial subsidiaries in Boston, San Francisco, and Cambridge UK, and serves smaller agrochemical clients through a GLP-compliant analytical testing arm.

The company's core offering is organized into three pillars: Drug Discovery (target validation through preclinical candidate nomination across small molecules, antibodies, and protein degraders), Drug Development (CMC analytical services, formulation, GMP manufacturing, stability studies, QP release, and regulatory affairs under GMP/GLP), and Contract Testing (GxP-compliant analytical services for pharma and agrochemical clients). Underlying the discovery pillar is an integrated technology stack that includes the proprietary TADAM deep-learning virtual screening model (processing 50M+ compounds per hour on NVIDIA H100 GPUs), structure-based drug design with advanced molecular dynamics, CADD/AI for ADMET and selectivity prediction, protein sciences (X-ray, cryo-EM, fragment-based discovery), high-content screening with computer vision, and a multi-omics hub covering genomics, transcriptomics, proteomics, and metabolomics. Recent platform additions include the CPSA cellular target engagement technology (launched November 2025) and a nanobody discovery partnership with Llamatech (June 2026).

Selvita monetizes via professional-services engagements delivered under full-time equivalent (FTE) or fee-for-service contracts of multi-year duration, with global regulatory compliance (FDA, EMA, ICH) and full IP retention by the client as standard terms. The company has scaled through a combination of organic expansion (Hexagon headquarters in Kraków 2023, Wrocław site 2024, US/UK subsidiaries from 2015-2016) and targeted M&A (BioCentrum 2008, Fidelta from Galapagos 2021, PozLab 2024), funded by a 2014 IPO (PLN 27.3M) and a 2020 secondary offering (EUR 20.6M). Most recently, Q1 2026 operating revenues were EUR 19.1M at a 14% EBITDA margin, with Drug Development growing 6% YoY while Drug Discovery declined against a softer European outsourced discovery market.

Name

Selvita

Legal name

Selvita S.A.

Website

https://selvita.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Selvita is a Poland-headquartered, publicly listed CRO delivering integrated drug discovery, drug development, and GxP-compliant analytical services to pharmaceutical, biotechnology, and agrochemical clients worldwide.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Testing Laboratories and Services (54138)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro industry

PRIMARYHLAGAAAB

Preclinical CROs (Discovery/Pharmacology/DMPK)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAAAC

Toxicology & Safety Assessment CROs (GLP)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAAAE

Central Laboratory & Clinical Trial Testing CROs

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAOAE

Quality Assurance, GxP Compliance & Auditing FSP

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

• Contract research services
• Drug discovery services
• Preclinical drug development
• Medicinal chemistry services
• Pharmaceutical R&D outsourcing

Headquarters

HQ city

Kraków

HQ country

Poland

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Drug Discovery Services: Integrated or standalone solutions spanning medicinal chemistry, biology, DMPK, and protein sciences from target validation to preclinical candidate nomination. Delivered via FTE or fee-for-service models.
2. Drug Development Services: CMC analytical services, formulation development, GMP manufacturing, stability studies, quality control and QP release for small molecules and biologics under GMP/GLP standards.
3. Contract Testing Services: GxP-compliant analytical testing services including method development, validation, impurity profiling, and bioanalysis for pharmaceutical and agrochemical clients.
4. Regulatory Affairs: Regulatory support for European market approval including dossier preparation, clinical trial applications, and registration services.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Selvita is an integrated contract research organization (CRO) providing drug discovery and drug development services to pharmaceutical and biotech companies. Service offerings span target validation through preclinical candidate nomination for small molecules, antibodies, and protein degraders, plus CMC analytical, formulation, GMP manufacturing, regulatory affairs, and GLP-compliant agroscience testing. Delivery models include both standalone studies and fully integrated discovery and development programs under FTE or fee-for-service contracts.

Product overview

Selvita is an integrated drug discovery and development service provider organized around three core service pillars: Drug Discovery Services, Drug Development Services, and specialized Agroscience Services. The Drug Discovery pillar encompasses AI-powered virtual screening (TADAM platform), computer-aided drug design, medicinal chemistry, protein sciences, pharmacology, DMPK, and omics capabilities. The Drug Development pillar provides CMC analytical services, formulation development, GMP manufacturing, quality control, and regulatory affairs support for small molecules and biologics. Specialty areas include nitrosamine/impurities testing, solid-state characterization, and scale-up chemistry. The company operates under GMP and GLP standards across facilities in Poland and Croatia, offering both standalone studies and fully integrated discovery and development programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Discovery Services Integrated drug discovery services from target validation to preclinical candidate nomination, supporting small molecules, antibodies, and protein degraders. Delivered via standalone studies or fully integrated discovery programs under FTE or fee-for-service models. For pharmaceutical and biotech companies.
• Drug Development Services End-to-end drug development and regulatory support including analytical services for small and large molecules, microbiology, formulation, and clinical trial batch manufacturing under GMP and GLP regulations. For pharmaceutical and biotech companies.
• Antibody Discovery Services Comprehensive antibody discovery including phage display libraries, antibody engineering, developability assessment, characterization, and bispecific antibody development. For biotech and pharmaceutical companies developing antibody therapeutics.
• Biologics Development Services Analytical services for biologics including protein characterization, immunogenicity testing, bioassays, biosimilarity assessment, and support for advanced modalities such as ADCs and oligonucleotides. For pharmaceutical and biotech companies.
• Agroscience Services GLP-compliant analytical services for crop protection agents including method development, physicochemical testing, impurity profiling, residue analysis, and certification. For agrochemical companies requiring product registration support.
• CPSA Target Engagement Technology Cellular Protein Structural Analysis (CPSA) - proprietary target engagement technology that measures drug-target interactions directly in cellular lysates. Offers simple, cost-effective, and scalable solution for assessing target engagement during drug discovery with comparable pharmacology to existing assays. For pharmaceutical and biotech researchers.
• Clinical Supply GMP Manufacturing Clinical supply GMP manufacturing of drug substance and drug product for early-stage clinical trials, including formulation development and packaging. For pharmaceutical companies preparing clinical-stage molecules.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature5 records

Partnerships

One partnership is on record.

• Llamatech Nanobody SolutionscoreStrategic or Co-development Partner · 2 June 2026Selvita expanded its antibody discovery portfolio through collaboration with Llamatech Nanobody Solutions, enabling enhanced capabilities in nanobody-based therapeutics development.

Scale indicators9 records

Recent moves15 records

Expansion highlights6 records

Broad incumbents

• Lonza Group: Global CDMO providing development and manufacturing services for small molecules, biologics, and cell/gene therapies. Overlaps with Selvita's Drug Development and biologics CMC services via PozLab, but operates at vastly larger scale and across more modalities.
• IQVIA: Largest global CRO with integrated clinical and R&D services, including laboratory, data, and technology capabilities. Competes with Selvita in early-phase research services but is far broader, with dominant clinical trial capabilities and technology platforms.
• Medpace Holdings: Mid-to-large CRO focused on clinical development for small and mid-sized biopharma. Less directly comparable in early discovery but competes for integrated outsourced R&D budgets at the same biotech customer segment as Selvita.
• WuXi AppTec: China-based global CRO/CDMO providing discovery, preclinical, and manufacturing services across small and large molecules. Directly competes with Selvita in integrated discovery and DMPK services and is far larger in scale and geographic reach.
• Charles River Laboratories: Large global CRO offering discovery, safety assessment, and manufacturing services with strong presence in preclinical research. Comparable to Selvita's discovery and toxicology/safety assessment services but at vastly larger scale and broader geographic reach.

Direct peers

• ChemPartner: Asia-headquartered CRO providing integrated drug discovery, medicinal chemistry, biology, and DMPK services to global pharma. Directly comparable to Selvita's core discovery service offering and target customer base, with similar FTE-based engagement model.
• Sygnature Discovery: UK-based integrated drug discovery CRO offering medicinal chemistry, biology, DMPK, and computational chemistry services. Closely comparable to Selvita in scale, geographic base (UK/Europe), and integrated discovery service model.
• Evotec SE: European-headquartered integrated drug discovery CRO offering medicinal chemistry, biology, DMPK, and integrated discovery partnerships to pharma/biotech. Directly comparable to Selvita in business model, service scope, and target customer base, though materially larger in scale.
• Eurofins Scientific: Global testing, laboratory, and CRO services provider with significant central laboratory and bioanalytical testing capabilities. Comparable to Selvita's Drug Development segment (CMC analytical, bioanalysis, GMP/GLP testing) and increasingly overlapping in early discovery services.
• Pharmaron: China-headquartered CRO/CDMO providing integrated drug discovery, preclinical, CMC, and manufacturing services to global pharma. Closely comparable to Selvita in integrated discovery-plus-development positioning, with overlapping services in medicinal chemistry, DMPK, and biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/selvitakrakow
• Facebookfacebook.com/130498986962386
• LinkedInlinkedin.com/company/selvita

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Selvita